J.P.
Last week, Biogen Inc (NASDAQ:BIIB) published its Phase 1b PRIME clinical trial coupled with supporting preclinical data in the latest volume of Nature. In …
Biogen Inc (NASDAQ:BIIB) indicated in its brief PR update yesterday that its pipeline drug aducanumab, the firm’s investigational treatment for early Alzheimer’s disease …
Healthcare analysts are weighing in on healthcare giants Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Biogen Inc (NASDAQ:BIIB). While one analyst becomes more bullish on Valeant as …
Credit Suisse analyst Alethia Young posits, “To acquire or to be acquired, that is the question for Biogen Inc (NASDAQ:BIIB).” Until an answer …
Relypsa Inc Yesterday, Relypsa Inc (NASDAQ:RLYP) announced that Galenica and Relypsa have entered into a definitive agreement under which Galenica will acquire Relypsa. …
Biogen Inc H.C.
Piper Jaffray’s healthcare analyst Joshua Schimmer is out today with research notes on biotech giants Biogen Inc (NASDAQ:BIIB) and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), as shares of …
Leerink Swann analyst Geoff Porges weighed in today with mixed views on healthcare giants Gilead Sciences, Inc.(NASDAQ:GILD) and Biogen Inc (NASDAQ:BIIB).
Yesterday, Jennifer asked is Valeant Pharmaceuticals the proverbial canary in the coal mine for the pharma industry? She came to the conclusion that …
